Next Article in Journal
Immune Response to SARS-CoV-2 mRNA Vaccines in an Open-Label Multicenter Study in Participants with Relapsing Multiple Sclerosis Treated with Ofatumumab
Next Article in Special Issue
GlnH, a Novel Antigen That Offers Partial Protection against Verocytotoxigenic Escherichia coli Infection
Previous Article in Journal
The Subunit AEC/BC02 Vaccine Combined with Antibiotics Provides Protection in Mycobacterium tuberculosis-Infected Guinea Pigs
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 10
Issue 12
10.3390/vaccines10122165
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Safety of Live Immunization in DiGeorge Syndrome: A Retrospective Single-Center Study in Korea, 2005–2021

by
Sung Min Lim
1,
Je Hee Shin
1,
Jee Yeon Baek
1,
Ji Young Lee
1,
Ji-Man Kang
1,2 and
Jong Gyun Ahn
1,2,*
1
Department of Pediatrics, Severance Children’s Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
2
Institute for Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul 03722, Republic of Korea
*
Author to whom correspondence should be addressed.
Vaccines 2022, 10(12), 2165; https://doi.org/10.3390/vaccines10122165
Submission received: 15 November 2022 / Revised: 13 December 2022 / Accepted: 14 December 2022 / Published: 16 December 2022
(This article belongs to the Special Issue Immunological Aspect regarding Vaccine Development and Uses)
Browse Figures
Versions Notes

Abstract

:
Live immunization is contraindicated in patients with DiGeorge syndrome (DGS). We retrospectively investigated the occurrence of adverse events after live immunization in patients with DGS in Korea. The data of patients matching the International Classification of Disease-10 code of DGS (D82.1) at Severance Hospital Seoul, Korea, were extracted; patients without genetically diagnosed DGS were excluded. Based on T cell immunity status, the included patients were categorized into group A (CD3 < 500 or CD8 < 200 cells/mm3); group B (CD3 ≥ 500 and CD8 ≥ 200 cells/mm3); or group C (unknown). Among 94 patients, 38 (~40%, group A: 8 [21%]; group B: 30 [79%]) underwent immunological testing and 73 (~80%) received at least one live immunization (measles–mumps–rubella vaccination was most common [66/94, ~70%]). Fifty adverse events (fever [n = 29], upper respiratory infection [n = 9], diarrhea [n = 4], rash [n = 3], thrombocytopenia [n = 3], injection site pus [n = 1], and febrile convulsion [n = 1]) were observed; 13 (26%) occurred in group A, with no significant difference in incidence between groups A and B. Serious adverse events, including intensive care unit hospitalization or death, or diseases due to vaccine strains were not observed. In this study, live immunization was well tolerated by patients with partial DGS.

1. Introduction

DiGeorge syndrome (DGS), also known as 22q11.2 deletion syndrome, is the most common microdeletion syndrome, with a prevalence of 1 in 4000 live births [1]. It is characterized by a wide range of clinical features, including congenital heart disease, hypoparathyroidism, facial dysmorphism, developmental delay, and immunodeficiency [1,2,3]. Patients with DGS show varying levels of T cell deficiencies (ranging from an absence of T cells to normal counts) and percentages due to thymic hypoplasia [4]. A very low T cell count (CD3 < 50 cells/mm3 or < 1–2%) is often regarded as complete DGS, whereas patients with partial DGS (pDGS) contain relatively higher T cell counts with a wide range of lymphoproliferative functions [5,6].
Adverse events (AEs) following live immunization (AEFLI) in patients with primary immunodeficiency diseases, such as vaccine-acquired measles, Bacillus Calmette–Guérin (BCG), and rotavirus infection, have been extensively studied [7,8,9,10]. Further, several studies have reported severe AEFLI, such as septicemia and pneumonia, following live attenuated varicella (VAR) vaccination [11,12], and serious BCGitis after BCG vaccination in patients with DGS [9]. Hence, in previous guidelines, live immunization was contraindicated for patients with T cell deficiencies, including DGS [13]. However, studies have indicated that live vaccinations, such as measles–mumps–rubella (MMR) and VAR vaccines, are relatively safe and well-tolerated in patients with pDGS [14,15,16].
The recent Infectious Disease Society of America (IDSA) and American Academy of Pediatrics (AAP) recommendations indicate that MMR and VAR vaccines should be considered if a patient with DGS has adequate T cell counts (≥ 500 and ≥ 200 CD3 and CD8 T cells/mm3, respectively) and exhibits normal mitogen response. However, patients with DGS with CD3 T cell counts < 500 cells/mm3 should not be administered any live vaccine [17,18].
Studies on the identification of AEs after BCG, rotavirus, and live-attenuated Japanese encephalitis virus (LJEV) vaccinations in patients with pDGS are limited, probably because BCG and LJEV are rarely included in the National Immunization Program (NIP) worldwide. In Korea, however, BCG and LJEV vaccines are included in the NIP, along with MMR and VAR vaccines. According to the 2018 Korea Disease Control and Prevention Agency report, the vaccination completion rate for that year was >95% for BCG, MMR, and VAR, and >90% for LJEV [19]. Although the rotavirus vaccine is not included in the NIP, a complete immunization rate of > 85% has been reported [20]. Such high vaccination coverage rates allow AE evaluation following various types of live immunizations in patients with DGS in Korea. Furthermore, the Korean Pediatric Society recommends consideration of MMR and VAR vaccines if a patient with DGS has adequate T cell counts (≥ 500 and ≥ 200 CD3 and CD8 T cells/mm3, respectively) and exhibits a normal mitogen response [21], similar to global guidelines. However, investigation of AEFLI in patients with DGS in Korea is limited. Hence, this study was conducted to examine AEFLI in patients with DGS in Korea.

2. Materials and Methods

2.1. Patient Characteristics

This retrospective study included patients diagnosed with DGS at Severance Hospital, Seoul, Korea, between 1 November 2005 and 31 July 2021. The data of patients matching the International Classification of Disease-tenth revision (ICD-10) code of DGS (D82.1) were extracted from the Severance Clinical Research Analysis Portal. Patients lacking genetic confirmation of 22q11.2 deletions were excluded. The patients' clinical information was collected by reviewing medical charts, while the immunization records were obtained from the NIP electronic record. In this study, data on five vaccines—namely BCG, rotavirus, MMR, VAR, and LJEV—were included. Demographic characteristics (age and sex); medical history (genetic testing and cardiac history); laboratory findings (all available blood test results, including lymphocyte subsets, complete blood counts, hormones, and electrolytes); and imaging findings (echocardiogram and cardiac computed tomography [CT]) were collected.
The patients were categorized into the following groups based on the current vaccination guidelines of the IDSA, AAP, and Korean Pediatric Society [17,18,21]: (1) group A, (CD3 < 500 or CD8 < 200 T cells/mm3) contraindicated for live vaccination; (2) group B, (CD3 ≥ 500 and CD8 ≥ 200 T cells/mm3) recommended for MMR and VAR vaccinations; and (3) group C, unknown immunity status. This study was approved by the Institutional Review Board of Severance Hospital (IRB number: 2021-2423-003), and the requirement for informed consent was waived due to the retrospective nature of the study.

2.2. Definition of AEFLI

An adverse event following immunization is defined by the World Health Organization (WHO) as “any untoward medical occurrence which follows immunization, and which does not necessarily have a causal relationship with the usage of the vaccine.” Moreover, serious AEs following immunization include any event resulting in death; life-threatening condition; persistent or significant disability/incapacity; requirement for intervention to prevent permanent impairment or damage; requirement for in-patient hospitalization; prolongation of existing hospitalization; or induction of a congenital anomaly/birth defect [22]. In this study, we adapted the above-mentioned definition of AEFLI. To investigate AEFLI, we reviewed the outpatient department and emergency room visits, hospitalizations, and medical records within 60 days (12 months for BCG vaccination) from the date of live vaccination. We defined serious AEFLI according to the WHO definition [22], excluding the requirement for in-patient hospitalization or prolongation of existing hospitalization, as the study was retrospective in nature and hospitalized patients were already selected as study participants.
The collected AEFLI data were analyzed according to the WHO assessment models. The 1999 WHO classification for adverse reactions includes six categories: very likely, probable, possible, unlikely, unrelated, and unclassifiable adverse reactions [23]. Additionally, the 2019 WHO causality classification includes the following: (A) consistent causal association to immunization, (B) indeterminate, (C) inconsistent with causal association to immunization, and (D) unclassifiable through an algorithm [24].

2.3. Statistical Analysis

Fisher’s exact test was used to identify any associations between immune status and AEFLI, and a p value of < 0.05 was considered statistically significant. All data analyses were performed using SPSS software for Windows, version 25.0 (SPSS Inc., Chicago, IL, USA).

3. Results

3.1. Study Population

During the study period, a total of 146 patients with the ICD-10 code D82.1 were identified. Of these, 94 patients with confirmed 22q11.2 deletion were selected as study participants (Figure 1). Table 1 shows the baseline characteristics of the participants. Fifty-one patients (54%) were male, and the genetic analysis was mostly (57%) performed using fluorescence in situ hybridization, with a median age of 7.9 months at genetic confirmation (interquartile range [IQR], 0.7–104.3). Moreover, 30 patients (32%) were treated for hypocalcemia; 69 (73%) presented with congenital heart diseases, including ventricular septal defect (n = 25), tetralogy of Fallot (n = 22), and interrupted aortic arch (n = 9); and 61 underwent surgery. Other common clinical features included facial dysmorphism (n = 50 [53%]), developmental delay (n = 38 [40%]), and epilepsy (n = 6 [6%]).
CD3 and CD8 T cell counts were available for approximately 40% (38/94) of patients; these patients had a median age of 2.8 months (IQR 1.0–75.5) when tested, and none of them had complete DGS (8 [21%] and 30 [79%] patients belonged to group A and B, respectively; Figure 1). Lymphocyte proliferation testing data were available for two patients, of which only one showed normal values. Furthermore, thymus imaging data based on cardiac CT or thoracic sonography were available for 28 patients (30%), of which 11 (27%) appeared to have a relatively small-sized thymus, while the remaining patients had a normal-sized thymus (Table 1).

3.2. Immunization Coverage

Table 2 shows immunization coverage among the study participants. Of the 94 participants, approximately 80% (73/94) received at least one live vaccination. Further, MMR vaccination accounted for the highest number of vaccinations (66/94 [70%]), followed by VAR (47/94 [50%]), BCG (45/94 [48%]), rotavirus (23/94 [24%]), and LJEV (18/94 [19%]) vaccinations. Approximately half of the vaccinated patients (36/73 [49%]) received a live vaccine before confirmation of 22q11.2 deletion.
In group A, 6 of the 8 (75%) patients received at least one live vaccination, with a total of 29 doses; half of these were vaccinated before diagnosis or lymphocyte subset analysis. MMR and VAR vaccination rates were the highest (63%, 5/8), followed by BCG (50%, 4/8), LJEV (38%, 3/8), and rotavirus (13%, 1/8) vaccination. In group B, 24 of the 30 (80%) patients had at least one live vaccination, with a total of 112 doses. Most patients (22/30 [73%]) received MMR vaccination followed by VAR (19/30 [63%]), BCG (18/30 [60%]), rotavirus (11/30 [37%]), and LJEV (9/30 [30%]) vaccinations. In group C, the MMR vaccination coverage rate was the highest (70% [39/56]), followed by the coverage rates of VAR (41% [23/56]), BCG (41% [23/56]), rotavirus (20% [11/56]), and LJEV (11% [6/56]) vaccinations.

3.3. AEFLI

Among 73 recipients of live vaccines, 17 showed a total of 50 AEFLI. The MMR, LJEV, VAR, BCG, and rotavirus vaccines were associated with 36%, 24%, 20%, 14%, and 6% AEFLI, respectively (Figure 2). AEs included fever (n = 29), upper respiratory infection (n = 9), diarrhea (n = 4), rash (n = 3), thrombocytopenia (n = 3), injection site pus (n = 1), and febrile convulsion (n = 1).
In group A, 13 AEFLI (LJEV, 5; MMR, 4; VAR, 2; BCG, 2) occurred after 29 live vaccine doses and in group B, 34 AEFLI (MMR, 13; VAR, 8; BCG, 5; LJEV, 5; rotavirus, 3) occurred after 112 live vaccine doses. No significant difference was observed in the incidence of AEs between groups A and B (45% vs. 30%, p = 0.14) (Table 3).
Applying the WHO 2019 causality assessment algorithm [24] to the 50 events, 12%, 58%, and 30% were categorized as consistent with live vaccination, indeterminate, and inconsistent, respectively. Moreover, serious AEs, such as intensive care unit hospitalization, death, and emergence of diseases caused by vaccine strains, were not observed.

4. Discussion

To the best of our knowledge, this is the first study to investigate AEFLI in patients with DGS in Korea. In addition to MMR and VAR vaccines, AEs after BCG, rotavirus, and LJEV vaccinations, which were rarely studied in the past, were also evaluated. Approximately 60% of patients with DGS received live vaccines without T cell function evaluation. Nevertheless, live vaccines were found to be generally well tolerated and safe in the present study, even in patients with moderate T cell deficiency.
Since the 2010s, the IDSA, AAP, and Korean Pediatric Society have recommended MMR and VAR vaccines for consideration in patients with pDGS with adequate T cell counts (≥500 CD3 T cells/mm3 and ≥200 CD8 T cells/mm3) and normal mitogen response [17,18,21]. Previous cohort studies have shown that unvaccinated individuals with pDGS experienced mild-to-moderate live vaccine-preventable illnesses [16,25]. Further, several studies have reported high rates of VAR and measles infections among unvaccinated patients, reflecting increased disease exposure and decreased herd immunity [14,26]. Therefore, live vaccines are beneficial in patients with pDGS with reasonable T cell function. However, depending on the degree of T cell deficiency, live vaccines can induce disease via the viral strains; hence, it is essential to evaluate T cell immunity before live vaccine inoculation. In the present study, T cell immunity status was evaluated in only approximately 40% of patients with DGS. Among patients who underwent the T cell test, 21% showed moderate deficiency (group A), which is currently contraindicated for live vaccines; however, no serious AEs, including infection by vaccine strains, were observed. This could be due to normal T cell function despite moderate deficiency. Although we did not test mitogen response (a test to evaluate T cell function), previous studies have reported normal mitogen response in patients with pDGS [15,25]. Nevertheless, further studies are needed to ascertain live vaccine safety in patients with DGS after thorough evaluation of mitogen response and CD3 and CD8 T cell immunity. Our study emphasized the need for immune screening before live vaccination in children diagnosed with DGS.
Most studies evaluating AEFLI in patients with pDGS have only been conducted for MMR and VAR vaccinations and demonstrate coverage rates of 47–88% and 25–75% [14,16,25], respectively. Further, AEFLI rates associated with MMR and VAR vaccinations are 7–22% and 20%, respectively, with no reported serious AEs [14,15,16]. In Korea, two MMR vaccine doses are administered at 1 year and 4–6 years of age, and VAR is inoculated at 1 year of age. In the present study, we observed that MMR vaccination coverage was the highest (70%), and the AE rates after MMR and VAR vaccinations were 18% (18/101) and 19% (10/53), respectively, with no serious AEs; these findings were consistent with those of previous studies.
Studies reporting AEFLI for BCG, rotavirus, and LJEV vaccines are limited. Although previous studies aimed to analyze AEs by including patients who received BCG and rotavirus vaccines, the sample sizes were small, and analyses of AEFLI were not sufficient [16,27]. In the Korean national mandatory vaccination schedule, BCG and Japanese encephalitis vaccines are administered within 4 weeks of age and after 1 year of age, respectively. For Japanese encephalitis, both live and inactivated vaccines are available. In addition, the rotavirus vaccine is selectively provided at 2, 4, and 6 months (for RotaTeq®) or 2 and 4 months (for Rotarix®) of age, and according to Korean national data in 2017, the rotavirus vaccine coverage rate was >85% [20,21]. The Korean vaccination schedule provided us with a unique opportunity to evaluate the AEs of live vaccines, such as BCG, rotavirus, and LJEV vaccines, which are rarely evaluated in patients with DGS. In the present study, although the live vaccine coverage rates were lower than the rates in the general Korean population [19], the number of participants was larger than that in previous studies. The rates of AEs following BCG, rotavirus, and LJEV vaccines were 16% (7/45), 6% (3/53), and 35% (12/34), respectively. Most symptoms were mild, and no serious AEs were identified. In group A, seven mild AEs were observed among the recipients of LJEV (5) and BCG (2) vaccinations, with fever being the most common (4/7). According to the 2019 WHO causality assessment algorithm, only one event—fever—was consistent with live vaccination in group A. Surveillance data for AEFI from 2011 to 2016 in South Korea showed that the average AEs reporting rate of BCG, MMR, VAR, and LJEV were 19, 1.7, 1.7, and 0.4 cases/100,000 doses, respectively [28]. Since it was a passively collected reporting system, there would have been many cases of missed reporting, and the AEFI reporting rates were lower than our results. However, while serious AEs including vaccine strain infection (BCG osteomyelitis, 4; disseminated BCG infection, 1; soft tissue infection, 1; infectious arthritis, 1; anaphylactic reaction, 1) have been reported in the surveillance system [28], there were no serious AEs in our study. Our results suggest that the current guidelines for MMR and VAR vaccines in patients with pDGS can also be applied to BCG, rotavirus, and LJEV vaccines.
This study has some limitations. First, it was a retrospective, single-center study; hence, it is inherently limited due to the non-random distribution of the study participants. Further, the sample size was relatively small. Second, immune screening data were lacking, which may have resulted in overestimation of immune status. Finally, we estimated AEFLI from medical visit records; this may have resulted in fewer AEFLI being identified and limited data for causality assessment. Nevertheless, our study analyzed the AEFLI of a wide range of live vaccines (BCG, rotavirus, LJEV, MMR, and VAR) simultaneously, in a population of patients with DGS.

5. Conclusions

In conclusion, our data indicated that live immunizations are well-tolerated by patients with pDGS and emphasized that immune screening tests should be encouraged before all live vaccinations in patients with DGS. Furthermore, this study of the safety of live vaccine immunization may contribute to alleviating vaccine hesitancy and facilitating greater coverage among patients with immunodeficiency. In this study, there was a lack of immune status evaluation data at the time of vaccination in patients with DGS. The evaluation of side effects, combined with T cell function evaluation in patients with DGS, would help us to obtain a better profile of the safety of live vaccination in that population. Additional multicenter, prospective, large-scale studies are required to validate our findings and provide further guidance for live immunizations in patients with DGS.

Author Contributions

Conceptualization, S.M.L., J.-M.K. and J.G.A.; Data curation, S.M.L., J.H.S., J.Y.B. and J.G.A.; Formal analysis, S.M.L., J.H.S. and J.Y.L.; Investigation, S.M.L.; Methodology, S.M.L.; Resources, J.Y.B.; Supervision, J.-M.K. and J.G.A.; Validation, J.Y.L.; Writing—original draft, S.M.L.; Writing—review and editing, S.M.L., J.-M.K. and J.G.A. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by a faculty research grant of Yonsei University College of Medicine (6-2021-0145).

Institutional Review Board Statement

The study was approved by the Institutional Review Board of Severance Hospital (IRB number: 2021-2423-003).

Informed Consent Statement

Patient consent was waived due to the retrospective nature of the study.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Kobrynski, L.J.; Sullivan, K.E. Velocardiofacial syndrome, DiGeorge syndrome: The chromosome 22q11.2 deletion syndromes. Lancet 2007, 370, 1443–1452. [Google Scholar] [CrossRef] [PubMed]
  2. Nissan, E.; Katz, U.; Levy-Shraga, Y.; Frizinsky, S.; Carmel, E.; Gothelf, D.; Somech, R. Clinical Features in a Large Cohort of Patients With 22q11.2 Deletion Syndrome. J. Pediatr. 2021, 238, 215–220. [Google Scholar] [CrossRef] [PubMed]
  3. McDonald-McGinn, D.M.; Sullivan, K.E. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine 2011, 90, 1–18. [Google Scholar] [CrossRef] [PubMed]
  4. Jawad, A.F.; Prak, E.L.; Boyer, J.; McDonald-McGinn, D.M.; Zachai, E.; McDonald, K.; Sullivan, K.E. A prospective study of influenza vaccination and a comparison of immunologic parameters in children and adults with chromosome 22q11.2 deletion syndrome (digeorge syndrome/velocardiofacial syndrome). J. Clin. Immunol. 2011, 31, 927–935. [Google Scholar] [CrossRef] [PubMed]
  5. Gennery, A.R. Immunological aspects of 22q11.2 deletion syndrome. Cell. Mol. Life. Sci. 2012, 69, 17–27. [Google Scholar] [CrossRef] [PubMed]
  6. Morsheimer, M.; Brown Whitehorn, T.F.; Heimall, J.; Sullivan, K.E. The immune deficiency of chromosome 22q11.2 deletion syndrome. Am. J. Med. Genet. A 2017, 173, 2366–2372. [Google Scholar] [CrossRef] [PubMed]
  7. Monafo, W.J.; Haslam, D.B.; Roberts, R.L.; Zaki, S.R.; Bellini, W.J.; Coffin, C.M. Disseminated measles infection after vaccination in a child with a congenital immunodeficiency. J. Pediatr. 1994, 124, 273–276. [Google Scholar] [CrossRef]
  8. Patel, N.C.; Hertel, P.M.; Estes, M.K.; Morena, M.; Petru, A.M.; Noroski, L.M.; Revell, P.A.; Hanson, I.C.; Paul, M.E.; Rosenblatt, H.M.; et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N. Engl. J. Med. 2010, 362, 314–319. [Google Scholar] [CrossRef] [Green Version]
  9. Sarmiento, J.D.; Villada, F.; Orrego, J.C.; Franco, J.L.; Trujillo-Vargas, C.M. Adverse events following immunization in patients with primary immunodeficiencies. Vaccine 2016, 34, 1611–1616. [Google Scholar] [CrossRef]
  10. Marciano, B.E.; Huang, C.Y.; Joshi, G.; Rezaei, N.; Carvalho, B.C.; Allwood, Z.; Ikinciogullari, A.; Reda, S.M.; Gennery, A.; Thon, V.; et al. BCG vaccination in patients with severe combined immunodeficiency: Complications, risks, and vaccination policies. J. Allergy Clin. Immunol. 2014, 133, 1134–1141. [Google Scholar] [CrossRef]
  11. Chaves, S.S.; Haber, P.; Walton, K.; Wise, R.P.; Izurieta, H.S.; Schmid, D.S.; Seward, J.F. Safety of varicella vaccine after licensure in the United States: Experience from reports to the vaccine adverse event reporting system, 1995–2005. J. Infect. Dis. 2008, 197 (Suppl. S2), S170–S177. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Waters, V.; Peterson, K.S.; LaRussa, P. Live viral vaccines in a DiGeorge syndrome patient. Arch. Dis. Child. 2007, 92, 519–520. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. National Center for Immunization and Respiratory Disease. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2011, 60, 1–64. [Google Scholar]
  14. Perez, E.E.; Bokszczanin, A.; McDonald-McGinn, D.; Zackai, E.H.; Sullivan, K.E. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics 2003, 112, e325. [Google Scholar] [CrossRef] [Green Version]
  15. Al-Sukaiti, N.; Reid, B.; Lavi, S.; Al-Zaharani, D.; Atkinson, A.; Roifman, C.M.; Grunebaum, E. Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome. J. Allergy Clin. Immunol. 2010, 126, 868–869. [Google Scholar] [CrossRef]
  16. Hofstetter, A.M.; Jakob, K.; Klein, N.P.; Dekker, C.L.; Edwards, K.M.; Halsey, N.A.; Baxter, R.; Williams, S.E.; Graham, P.L., 3rd; LaRussa, P. Live vaccine use and safety in DiGeorge syndrome. Pediatrics 2014, 133, e946–e954. [Google Scholar] [CrossRef] [Green Version]
  17. Kimberlin, D.W. Red Book: 2018–2021 Report of the Committee on Infectious Diseases, 31st ed.; American Academy of Pediatrics: Itasca, IL, USA, 2018; ISBN 978-161-002-1463. [Google Scholar]
  18. Rubin, L.G.; Levin, M.J.; Ljungman, P.; Davies, E.G.; Avery, R.; Tomblyn, M.; Bousvaros, A.; Dhanireddy, S.; Sung, L.; Keyserling, H.; et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Infect. Dis. 2014, 58, e44–e100. [Google Scholar] [CrossRef] [Green Version]
  19. Lee, J.; Jeong, H.; Kim, S.; Yu, J.; Kim, G. National childhood vaccination coverage among children aged 1–3 and 6 years in Korea, 2018. Public Health Wkly. Rep. 2019, 12, 1548–1558. [Google Scholar]
  20. Lee, S.G.; Jeon, S.Y.; Park, K.S. Rotavirus Vaccine Coverage and Related Factors. J. Korean Soc. Matern. Child Health 2019, 23, 175–184. [Google Scholar] [CrossRef]
  21. Choi, E.W.; Park, S.E.; Kim, Y.J.; Jo, D.S.; Kim, Y.K.; Eun, B.W.; Lee, T.J.; Lee, J.; Kim, K.H.; Cho, H.K. Immunization Guideline: 2018 Report of the Committee on Infectious Diseases, 9th ed.; The Korean Pediatric Society: Seoul, Republic of Korea, 2018; pp. 32–33. [Google Scholar]
  22. World Health Organization. Global Manual on Surveillance of Adverse Events Following Immunization, 2016 update ed.; World Health Organization: Geneva, Switzerland, 2014; ISBN 978-92-4-150776-9. [Google Scholar]
  23. World Health Organization. Regional Office for the Western Pacific. Immunization Safety Surveillance: Guidelines for Managers of Immunization Programmes on Reporting and Investigating Adverse Events Following Immunization; World Health Organization: Geneva, Switzerland, 1999; ISBN 9290611820. [Google Scholar]
  24. World Health Organization. Causality Assessment of an Adverse Event Following Immunization (AEFI): User Manual for the Revised WHO Classification, 2nd ed.; World Health Oragnization: Geneva, Switzerland, 2019; ISBN 978-92-4-151699-0. [Google Scholar]
  25. Moylett, E.H.; Wasan, A.N.; Noroski, L.M.; Shearer, W.T. Live viral vaccines in patients with partial DiGeorge syndrome: Clinical experience and cellular immunity. Clin. Immunol. 2004, 112, 106–112. [Google Scholar] [CrossRef]
  26. Seward, J.F.; Watson, B.M.; Peterson, C.L.; Mascola, L.; Pelosi, J.W.; Zhang, J.X.; Maupin, T.J.; Goldman, G.S.; Tabony, L.J.; Brodovicz, K.G.; et al. Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA 2002, 287, 606–611. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Miranda, M.; Matrins, A.T.; Carvalho, S.; Serra-Caetano, A.; Esteves, I.; Marques, J.G. Live Vaccine in Children with DiGeorge/22q11.2 Deletion Syndrome. Acta. Med. Port. 2019, 32, 514–519. [Google Scholar] [CrossRef] [PubMed]
  28. Kim, M.K.; Lee, Y.K.; Kim, T.E.; Kong, I.; Yang, H.J.; Suh, E.S. Surveillance and compensation claims for adverse events following immunization from 2011 to 2016 in the Republic of Korea. Clin. Exp. Vaccine Res. 2017, 6, 146–155. [Google Scholar] [CrossRef] [PubMed]
Vaccines 10 02165 g001 550
Figure 1. Flow chart of the study. Abbreviations: ICD-10, International Classification of Disease-10.
Figure 1. Flow chart of the study. Abbreviations: ICD-10, International Classification of Disease-10.
Vaccines 10 02165 g001
Vaccines 10 02165 g002 550
Figure 2. Adverse events following live immunization (n = 50). Abbreviations: BCG, Bacillus Calmette–Guérin; MMR, measles-mumps-rubella; VAR, live-attenuated varicella; LJEV, live-attenuated Japanese encephalitis virus.
Figure 2. Adverse events following live immunization (n = 50). Abbreviations: BCG, Bacillus Calmette–Guérin; MMR, measles-mumps-rubella; VAR, live-attenuated varicella; LJEV, live-attenuated Japanese encephalitis virus.
Vaccines 10 02165 g002
Table
Table 1. Characteristics of the study population.
Table 1. Characteristics of the study population.
CharacteristicsN (%) or Median (IQR)
Sex (Male), n (%)51 (54.3)
Age of disease confirmation, median (IQR), month7.9 (0.7–104.3)
Chromosome 22q11.2 deletion, n (%)94 (100)
FISH54 (57.4)
MLPA26 (27.7)
Others14 (14.9)
Cardiac disease, n (%)69 (73.4)
Ventricular septal defect25 (36.2)
Tetralogy of Fallot22 (31.9)
Interrupted aortic arch9 (13.0)
Others13 (18.8)
S/p operation61 (88.4)
Hypocalcemia, n (%)30 (31.9)
Facial dysmorphism, n (%)50 (53.2)
Developmental delay, n (%)38 (40.4)
Epilepsy, n (%)6 (6.4)
Schizophrenia, n (%)2 (2.1)
Death, n (%)5 (5.3)
No. of lymphocyte subsets test, n (%)38 (40.4)
Age at test, median (IQR), month2.8 (1.0–75.5)
CD3 ≥ 500 and CD8 ≥ 200 (cells/mm3), n (%)30 (79)
CD3 (cells/mm3), median (range)1425 (536–4234)
CD8 (cells/mm3), median (range)421 (242–2001)
CD4 (cells/mm3), median (range)938 (231–3001)
CD3 < 500 or CD8 < 200 (cells/mm3), n (%)8 (21)
CD3 (cells/mm3), median (range)378 (205–497)
CD8 (cells/mm3), median (range)179 (35–198)
CD4 (cells/mm3), median (range)245 (139–345)
<50 CD3 (cells/mm3), n (%)0 (0)
Mitogen response, n (%)2 (2.1)
>101 (50)
≤101 (50)
Thymus screening, n (%)28 (29.7)
Hypoplasia or absent11 (39.3)
Normal17 (60.7)
Abbreviations: FISH, fluorescence in situ hybridization; MLPA, multiple ligation probe amplification; IQR, interquartile range.
Table
Table 2. Live immunization coverage in the study population.
Table 2. Live immunization coverage in the study population.
Group A (n = 8) aGroup B (n = 30) bGroup C (n = 56) cTotal (n = 94)
Immunized Patients,
N (%)		Vaccine
Doses (N)		Immunized Patients,
N (%)		Vaccine
Doses (N)		Immunized Patients,
N (%)		Vaccine
Doses (N)		Immunized Patients,
N (%)		Vaccine
Doses (N)
BCG4 (50)418 (60)1823 (41)2345 (48)45
Rotavirus1 (13)211 (37)2511 (20)2623 (24)53
MMR5 (63)1022 (73)3239 (70)5966 (70)101
VAR5 (63)719 (63)2023 (41)2647 (50)53
LJEV3 (38)69 (30)176 (11)1118 (19)34
Total d6 (75)2924 (80)11243 (77)14573 (78)286
Abbreviations: BCG, Bacillus Calmette–Guérin; MMR, measles–mumps–rubella; VAR, live-attenuated varicella; LJEV, live-attenuated Japanese encephalitis virus. a Patients with moderate T cell deficiency, CD3 < 500 or CD8 < 200 cells/mm3. b Patients with mild-to-normal T cell deficiency, CD3 ≥ 500 and CD8 ≥ 200 cells/mm3. c Patients without lymphocyte subset results. d The number of patients who received at least one live immunization in each group.
Table
Table 3. Adverse events following live immunization and causality assessments.
Table 3. Adverse events following live immunization and causality assessments.
Group aSexAge (Months)Vaccination TypeAdverse EventsInterval Day(s) bAlgorithm cCausality 2019 cCausality 1999 d
AF96LJEVfever1consistentA1very likely
AM13LJEVfever (UTI)35inconsistentCunlikely
AM13LJEVcough35indeterminateB2unlikely
AF12MMRfever8indeterminateB1unlikely
AF12MMRdiarrhea8indeterminateB2possible
AF12VARdiarrhea8indeterminateB2unlikely
AF12VARfever8indeterminateB1possible
AF12LJEVfever8indeterminateB1possible
AF12LJEVdiarrhea8indeterminateB2unlikely
AF3BCGfever (rhinovirus)15inconsistentCunrelated
AF3BCGcough (rhinovirus)15inconsistentCunrelated
AM12MMRfever19indeterminateB1unlikely
AM12MMRcough19indeterminateB2unlikely
BM3BCGinjection site pus e47consistentA1very likely
BF1BCGrash94indeterminateB2possible
BF12MMRfever1consistentA1very likely
BF13MMRfever8indeterminateB1possible
BM59MMRfever19indeterminateB2unlikely
BF16MMRcough28indeterminateB2unlikely
BF16MMRfever28indeterminateB2unlikely
BF12VARfever0consistentA1very likely
BF13VARfever8indeterminateB1possible
BM12VARfever13indeterminateB2unlikely
BM28LJEVfever2consistentA1very likely
BM16LJEVfebrile convulsion f51indeterminateB2unlikely
BM0BCGfever (UTI)52inconsistentCunrelated
BF6BCGfever (RSV)119inconsistentCunrelated
BF6BCGcough (RSV)119inconsistentCunrelated
BM7Rotafever (UTI)37inconsistentCunrelated
BF7Rotacough49indeterminateB2unlikely
BF7Rotafever49indeterminateB2unlikely
BM12MMRfever13indeterminateB2unlikely
BM12MMRcough (RSV)25inconsistentCunrelated
BM12MMRfever (RSV)25inconsistentCunrelated
BM13MMRthrombocytopenia g (post cardiac operation condition)30inconsistentCunrelated
BF12MMRrash33indeterminateB2probable
BF12MMRthrombocytopenia33indeterminateB2probable
BF12MMRfever33indeterminateB2unlikely
BM56MMRfever (rhinovirus)48inconsistentCunlikely
BM12VARcough (RSV)25inconsistentCunrelated
BM12VARfever (RSV)25inconsistentCunrelated
BF12VARrash33indeterminateB1probable
BF12VARthrombocytopenia33indeterminateB2unlikely
BF12VARfever33indeterminateB2unlikely
BM25LJEVfever21inconsistentCunrelated
BF28LJEVcough21indeterminateB2unlikely
BM16LJEVfever51inconsistentCunrelated
CM13MMRfever8indeterminateB1unlikely
CM27LJEVfever1consistentA1very likely
CM27LJEVdiarrhea1indeterminateB1probable
Abbreviations: BCG, Bacillus Calmette–Guérin; MMR, measles-mumps-rubella; VAR, live-attenuated varicella; LJEV, live-attenuated Japanese encephalitis virus; M, male; F, female; UTI, urinary tract infection; RSV, respiratory syncytial virus. a Categorized by results of lymphocyte subsets; group A [CD3 ≥ 500 and CD8 ≥ 200 (cells/mm3)], group B [CD3 < 500 or CD8 < 200 (cells/mm3)], and group C without lymphocyte subset results. b The number of days between the date of live immunization and the occurrence of adverse events. c WHO causality assessment, 2019; A1, vaccine product-related reaction; B1, temporal relationship is consistent but there is insufficient definitive evidence for vaccine causing event; B2, qualifying factors result in conflicting trends of consistency and inconsistency with causal association to immunization; C, coincidental underlying or emerging condition(s), or condition(s) caused by exposure to something other than vaccine. d WHO Immunization safety surveillance, 1999..e No systemic symptoms and no requirement of systemic antibiotics. f Simple febrile convulsion; no need for anti-epileptic drugs or hospitalization. g Platelet counts were <150,000/μL and >50,000/μL in all cases.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lim, S.M.; Shin, J.H.; Baek, J.Y.; Lee, J.Y.; Kang, J.-M.; Ahn, J.G. Safety of Live Immunization in DiGeorge Syndrome: A Retrospective Single-Center Study in Korea, 2005–2021. Vaccines 2022, 10, 2165. https://doi.org/10.3390/vaccines10122165

AMA Style

Lim SM, Shin JH, Baek JY, Lee JY, Kang J-M, Ahn JG. Safety of Live Immunization in DiGeorge Syndrome: A Retrospective Single-Center Study in Korea, 2005–2021. Vaccines. 2022; 10(12):2165. https://doi.org/10.3390/vaccines10122165

Chicago/Turabian Style

Lim, Sung Min, Je Hee Shin, Jee Yeon Baek, Ji Young Lee, Ji-Man Kang, and Jong Gyun Ahn. 2022. "Safety of Live Immunization in DiGeorge Syndrome: A Retrospective Single-Center Study in Korea, 2005–2021" Vaccines 10, no. 12: 2165. https://doi.org/10.3390/vaccines10122165

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop